IMM:ASX
Immutep Ltd
AU$0,063
arrow_downward
-11,27%(-0,0080) 1G
28 Nis, 16:10:30 GMT+10 · AUD
search
Tüm semboller
1G
5G
1A
6A
Yıl Başından Beri
1Y
5Y
MAKS
| Sembol | Fiyat | Değişiklik | Değişiklik % |
|---|
insights_autoIMM ile ilgili en önemli analizler oluşturuluyor...
Açık
AU$0,07
Yüksek
AU$0,07
Düşük
AU$0,06
Piy. değ.
94,17 Mn
Ort. hacim
74,27 Mn
İşlem Hacmi
47,54 Mn
52 haftalık en yüksek
AU$0,47
52 haftalık en düşük
AU$0,03
HBK
-AU$0,06
Tedavüldeki hisse senedi sayısı
1,47 Mr
Çalışan sayısı
19
Haberler
Web genelindeki kaynaklardan
24/7 Wall St.
·
10 dakika önce
When April Delivers 5% Gains, the Rest of the Year Has Never Been Negative. Here's What History Says About May
Stock Titan
·
10 dakika önce
GRAIL (NASDAQ: GRAL) outlines CEO transition, director elections in 2026 proxy
Simply Wall Street
·
12 dakika önce
Talen AWS Nuclear Deal Supports Long Term Growth And Valuation Upside
Morningstar
·
19 dakika önce
Meridian Holdings (NASDAQ:MRDN) Q1 Results Reflect Growing Profitability and Balance Sheet Stability
Profil
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis. Wikipedia
Immutep Ltd hakkında
Yapay zeka içeriklerinde hata olabilir. Daha fazla bilgi